Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancers of the urothelial tract. The company operates within the biopharmaceutical and oncology industries, with a specific emphasis on urology-focused cancers that historically have relied on surgical intervention rather than pharmacological treatment. Its core strategy centers on the use of its proprietary drug delivery technology to enable sustained exposure of therapeutic agents to the urinary tract.
The company’s primary revenue driver is JELMYTO® (mitomycin) for pyelocalyceal solution, an FDA-approved therapy for the treatment of low-grade upper tract urothelial cancer (UTUC). UroGen was founded in 2004 and has evolved from an early-stage research-focused entity into a commercial-stage company following regulatory approval of its lead product. Its differentiation lies in addressing cancers with high recurrence rates using localized, sustained-release drug formulations designed to reduce the need for invasive surgery.
Business Operations
UroGen’s operations are organized around the development and commercialization of proprietary oncology therapeutics utilizing its RTGel® reverse thermal hydrogel technology. The company generates revenue primarily through sales of JELMYTO®, which is marketed in the United States for patients with low-grade UTUC. Additional pipeline candidates are in late-stage clinical development, targeting broader urothelial cancer indications.
The company conducts commercial activities primarily in the United States, while significant research and development activities are supported by operations in Israel. UroGen maintains full ownership of its core technologies and product candidates, with no reliance on large-scale joint ventures for its lead programs. Its subsidiary, UroGen Pharma, Inc., supports U.S.-based commercial and corporate operations.
Strategic Position & Investments
UroGen’s strategic direction is focused on expanding its uro-oncology franchise by advancing late-stage clinical programs that leverage its sustained-release technology platform. A key growth initiative is the development of UGN-102, an investigational formulation of mitomycin designed for the treatment of low-grade, intermediate-risk non–muscle-invasive bladder cancer (NMIBC), which has completed Phase 3 clinical evaluation.
The company continues to invest heavily in clinical development rather than acquisitions, prioritizing internal pipeline expansion over external portfolio diversification. Its emerging focus areas include additional urothelial cancer indications and lifecycle management of its approved and investigational products, positioning the company to address larger patient populations within urologic oncology.
Geographic Footprint
UroGen is headquartered in Princeton, New Jersey, which serves as its primary corporate and commercial hub. The company also maintains a significant presence in Israel, where key research and development functions are based. Its commercial market presence is currently concentrated in North America, reflecting the approved indication for its lead product.
While UroGen does not yet have broad international commercialization, its clinical development programs and intellectual property strategy are structured to support potential future expansion into Europe and other global markets, subject to regulatory approvals and strategic partnerships.
Leadership & Governance
UroGen is led by an executive team with experience across biopharmaceutical development, oncology commercialization, and corporate finance. The leadership team emphasizes a strategy centered on disciplined clinical execution, targeted commercialization, and innovation in drug delivery for underserved cancer indications.
Key executives include:
- Liz Barrett – President & Chief Executive Officer
- Mark Schoenebaum – Chief Financial Officer
- Eric Mansour – Chief Commercial Officer
- Mark Soloway – Chief Medical Advisor
The company is governed by a board with expertise spanning life sciences, regulatory affairs, and capital markets, supporting its transition from a development-stage company to a sustainable commercial organization.